Coordinated activation of toll-like receptor8 (TLR8) and NLRP3 by the TLR8 agonist, VTX-2337, ignites tumoricidal natural killer cell activity

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Dietsch, Gregory N ^a   Lu, Hailing ^b,c   Yang, Yi ^b   Morishima, Chihiro ^b   Chow, Laura Q ^b   Disis, Mary L ^b   Hershberg, Robert M ^a  

^a VentiRx Pharmaceuticals   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Immune Design Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CETUXIMAB; CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MOTOLIMOD; NATURAL KILLER CELL RECEPTOR NKG2D; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; BENZAZEPINE DERIVATIVE; CARRIER PROTEIN; FC RECEPTOR; NLRP3 PROTEIN, HUMAN; VTX-2337;

ADULT; ANIMAL EXPERIMENT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DOSE ESCALATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; LYMPHOCYTE ACTIVATION; MALE; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); AGONISTS; ANIMAL; BIOSYNTHESIS; CYTOTOXICITY; DEGRANULATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; IMMUNOLOGY; K-562 CELL LINE; MACACA FASCICULARIS; METABOLISM; MONONUCLEAR CELL; NEOPLASM; TUMOR CELL LINE;

ANIMALS; BENZAZEPINES; CARRIER PROTEINS; CASPASE 1; CELL DEGRANULATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MALE; NEOPLASMS; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; RECEPTORS, IGG; TOLL-LIKE RECEPTOR 8;

EID: 84960459109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148764     Document Type: Article

References (30)

1. Diefenbach A, Raulet DH. The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev. 2002; 188: 9-21. PMID: 12445277
2. Kaifu T, Escaliere B, Gastinel LN, Vivier E, Baratin M. B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 2011; 68: 3531-9. doi: 10.1007/s00018-011-0802-7 PMID: 21877119
3. Lu H, Dietsch GN, Matthews MA, Yang Y, Ghanekar S, Inokuma M, et al. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res. 2012; 18: 499-509. doi: 10. 1158/1078-0432.CCR-11-1625 PMID: 22128302
4. Chen X, Trivedi PP, Ge B, Krzewski K, and Strominger JL. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity. PNAS. 2007; 104: 6329-34. PMID: 17395718
5. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009; 58(11): 1853-64. doi: 10.1007/s00262-009-0697-4 PMID: 19319529
6. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013; 19: 1858-72. doi: 10.1158/1078-0432.CCR-12-2426 PMID: 23444227
7. Zhou Z, Zhang C, Zhang J, Tian Z. Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PLoSOne. 2012; 7(5): e36928.
8. Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen Y, Toso J, Jonak Z, Chang H, Robertson M. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother.2013; 62: 1073-1082. doi: 10.1007/s00262-013-1403-0 PMID: 23604103
9. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008; 9: 847-56. doi: 10.1038/ni.1631 PMID: 18604214
10. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006; 440: 237-41. PMID: 16407889
11. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009; 10: 241-7. doi: 10.1038/ni.1703 PMID: 19221555
12. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol. 2007; 7: 31-40. PMID: 17186029
13. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15: 1170-8. doi: 10.1038/nm.2028 PMID: 19767732
14. Lu H, Knutson KL, Gad E, Disis ML. The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens. Cancer Res. 2006; 66: 9754-61. PMID: 17018635
15. Mueller SC, Marz R, Schmolz M, Drewelow B. Intraindividual long term stability and response corridors of cytokines in healthy volunteers detected by a standardized whole-blood culture system for bed-side application. BMC Med Res Methodol. 2012; 12: 112. doi: 10.1186/1471-2288-12-112 PMID: 22853196
16. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005; 106: 376-83. PMID: 15755898
17. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J of Immunol Methods. 2004; 294: 15-22.
18. Liu J, Xu C, Hsu LC, Luo Y, Xiang R, Chuang TH. A five-amino-acid motif in the undefined region of the TLR8 ectodomain is required for species-specific ligand recognition. Mol Immunol. 2010; 47: 1083-1090. doi: 10.1016/j.molimm.2009.11.003 PMID: 20004021
19. Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling. Nat Immunol. 2012; 13: 333-2. doi: 10.1038/ni.2237 PMID: 22430786
20. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8 T cells. Cancer Immunol Immunother. 2013; 62: 1347-57. doi: 10.1007/s00262-013-1437-3 PMID: 23685782
21. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009; 183: 787-91. doi: 10.4049/jimmunol.0901363 PMID: 19570822
22. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013; 19: 57-64. doi: 10.1038/nm.2999 PMID: 23202296
23. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest. 2011; 121: 3609-22. doi: 10.1172/JCI45816 PMID: 21841316
24. Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother. 2012; 61: 1395-1405 doi: 10.1007/s00262-011-1197-x PMID: 22270713
25. Stoll S, Jonuleit H, Schmitt E, Müller G, Yamauchi H, Kurimoto M, et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol. 1998; 28: 3231-9. PMID: 9808192
26. Spranger S, Javorovic M, Bürdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol. 2010; 185: 738-47. doi: 10.4049/jimmunol.1000060 PMID: 20511554
27. Pufnock JS, Cigal M, Rolczynski LS, Andersen-Nissen E, Wolfl M, McElrath MJ, et al. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8 + T cells retaining CD28. Blood. 2011; 117: 6542-51. doi: 10.1182/blood-2010-11-317966 PMID: 21493800
28. Roda JM, Parihar R, Carson WE 3rd. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol. 2005; 175: 1619-27. PMID: 16034101
29. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol. 2005; 175: 1636-42. PMID: 16034103
30. Wysocka M, Dawany N, Benoit B, Kossenkov AV, Troxel AB, Gelfand JM, et al. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferongamma: implications for therapy of cutaneous T-cell lymphoma. Leuk Lymphoma. 2011; 52: 1970-9. doi: 10.3109/10428194.2011.582202 PMID: 21942329